Transfer of the dental pulp cell banking and conditioned medium business to the Doujin Group and concentration of research and development
First written in FY2020. 1 of 4 entries say "Restated". Latest entry: FY2021-Q3.
No other company in this theme has enough history to compare yet.
- FY2021-Q3ReframedAnnual report
「Regarding the postponement of the share transfer to 同仁グループ announced by the company on 30 September 2020, the transferee was changed from 同仁グループ to リバース, which was considered a more suitable transferee. The company entered into a share transfer agreement with リバース on 12 November 2020 and completed the transfer on the same day.」
The plan to transfer the dental pulp cell bank and conditioned medium businesses was reorganized, with the transferee changed from 同仁グループ to リバース, and the transfer was completed. - FY2021-Q2SoftenedAnnual report
「The two companies agreed that more time was needed to prepare, and therefore decided to postpone the execution date of the share transfer from the originally scheduled 30 September 2020 to 31 December 2020.」
As part of the business restructuring involving the transfer of セルテクノロジー's dental pulp cell bank and conditioned medium businesses to 同仁グループ, the execution date was postponed to establish the collaboration framework. - FY2021-Q1RestatedAnnual report
「As a result, the company agreed to acquire the business of セルテクノロジー relating to the research and development of regenerative medicine products using dental pulp stem cells, maximize its value by concentrating management resources on it, and accelerate the growth and maximize the value of the dental pulp cell bank® and dental pulp stem cell conditioned medium businesses by combining them with similar businesses of 同仁グループ and sharing the business expertise and networks cultivated by both companies over many years.」
In connection with the transfer of セルテクノロジー, the company reconfirmed its business restructuring policy of consolidating research and development of regenerative medicine products in-house and separating the dental pulp cell bank and conditioned medium businesses for collaboration with 同仁グループ. - FY2020First statedAnnual report
「As a result, the company agreed to acquire the business of セルテクノロジー relating to the research and development of regenerative medicine products using dental pulp stem cells, maximize its value by concentrating management resources on it, and accelerate the growth and maximize the value of the dental pulp cell bank® and dental pulp stem cell conditioned medium businesses by combining them with similar businesses of 同仁グループ and sharing the business expertise and networks cultivated by both companies over many years.」
In connection with the sale of セルテクノロジー, a business restructuring policy was presented for the first time under which research and development of regenerative medicine products would be consolidated in-house, while the dental pulp cell bank and conditioned medium businesses would be separated for collaboration with 同仁グループ.